- AI
- Molecular Imaging
- CT
- X-Ray
- Ultrasound
- MRI
- Facility Management
- Mammography
Software firm allies with Amersham
Mirada Solutions of Oxford, U.K., and Amersham Health have agreed to develop image analysis software to support the British pharmaceutical company's molecular diagnostic products. The software will draw from technology underlying Mirada's MiraView
Mirada Solutions of Oxford, U.K., and Amersham Health have agreed to develop image analysis software to support the British pharmaceutical company's molecular diagnostic products. The software will draw from technology underlying Mirada's MiraView multimodality workstation to provide quantitative and reproducible methods of image analysis. Molecular imaging promises exact and sensitive information, leading to earlier and more accurate diagnoses-but only if the data can be quantified, according to the two companies. Although Mirada has established relationships with hardware manufacturers, this is its first with a company engaged primarily in pharmaceuticals.
Can Portable Dual-Energy X-Ray be a Viable Alternative to CT in the ICU?
September 13th 2024The use of a portable dual-energy X-ray detector in the ICU at one community hospital reportedly facilitated a 37.5 percent decrease in chest CT exams in comparison to the previous three months, according to research presented at the American Society of Emergency Radiology (ASER) meeting in Washington, D.C.
New Meta-Analysis Examines MRI Assessment for Treatment of Esophageal Cancer
September 12th 2024Diffusion-weighted MRI provided pooled sensitivity and specificity rates of 82 percent and 81 percent respectively for gauging patient response to concurrent chemoradiotherapy for esophageal cancer, according to new meta-analysis.
Study for Emerging PET/CT Agent Reveals ‘New Standard’ for Detecting Clear Cell Renal Cell Carcinoma
September 11th 2024Results from a multicenter phase 3 trial showed that the PET/CT imaging agent (89Zr)Zr-girentuximab had an 85.5 percent mean sensitivity rate for the diagnosis of clear cell renal cell carcinoma.
Can Radiomics and Autoencoders Enhance Real-Time Ultrasound Detection of Breast Cancer?
September 10th 2024Developed with breast ultrasound data from nearly 1,200 women, a model with mixed radiomic and autoencoder features had a 90 percent AUC for diagnosing breast cancer, according to new research.
